Ian Jacobson, CEO of Juno Pharmaceuticals, presents the company’s business model of in-licensing and repurposing generic products. He highlights the successful development of the company’s affiliates in Australia, the UK and South Africa, and his plans to refocus efforts on the Canadian market in the near future, aiming to launch additional products to the market.
Since its creation in 2011, Juno Pharmaceuticals has experienced a tremendous expansion. What have been some of main critical developments of the company’s five-year history?
"We will focus more of our efforts on the market in Canada, 2018 promises to be the turning year for this."
